Senolytics prevent caveolar Ca V 3 . 2‐RyR axis malfunction in old vascular smooth muscle
Aging Cell · 2023-11 · 22 (11)
DOI: 10.1111/acel.14002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, online erschienen am 14.10.2023. Verfasst von Jie Lin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, The first Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Caveolae. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aging is a major risk factor for cardiovascular diseases. Our previous studies demonstrate that aging impairs the caveolar T‐type Ca V 3.2‐RyR axis for extracellular Ca 2+ influx to trigger Ca 2+ sparks in vascular smooth muscle cells (VSMCs). We hypothesize that the administration of senolytics, which can selectively clear senescent cells, could preserve the caveolar Ca V 3.2‐RyR axis in aging VSMCs. In this study, 10‐month‐old mice were administered the senolytics cocktail consisting of dasatinib (5 mg/kg) and quercetin (50 mg/kg) or vehicle bi‐weekly for 4 months. Using VSMCs from mouse mesenteric arteries, we found that Ca 2+ sparks were diminished after caveolae disruption by methyl‐β‐cyclodextrin (10 mM) in cells from D + Q treated but not vehicle‐treated 14‐month‐old mice. D + Q treatment promoted the expression of Ca V 3.2 in 14‐month‐old mesenteric arteries. Structural analysis using electron tomography and immunofluorescence staining revealed the remodeling of caveolae and co‐localization of Ca V 3.2‐Cav‐1 in D + Q treatment aged mesenteric arteries. In keeping with theoretical observations, Ca v 3.2 channel inhibition by Ni 2+ (50 μM) suppressed Ca 2+ in VSMCs from the D + Q group, with no effect observed in vehicle‐treated arteries. Our study provides evidence that age‐related caveolar Ca V 3.2‐RyR axis malfunction can be alleviated by pharmaceutical intervention targeting cellular senescence. Our findings support the potential of senolytics for ameliorating age‐associated cardiovascular disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology Department, The first Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Sports Medicine Center, Huazhong University of Science and Technology Union Shenzhen Hospital, the 6th affiliated Hospital of Shenzhen University Medical School, Shenzhen, China.
- Department of Gastroenterology, Huazhong University of Science and Technology Union Shenzhen Hospital, the 6th affiliated Hospital of Shenzhen University Medical School, Shenzhen, China.
- Neurology Department, Huazhong University of Science and Technology Union Shenzhen Hospital, the 6th affiliated Hospital of Shenzhen University Medical School, Shenzhen, China.
- Department of Pain Medicine and Shenzhen Municipal Key Laboratory for Pain Medicine, Huazhong University of Science and Technology Union Shenzhen Hospital, the 6th affiliated Hospital of Shenzhen University Medical Scho…
- Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian Province, China.
ORCID-Profile: Gang Fan
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lin, J., Guo, W., Luo, Q., Zhang, Q., Wan, T., Jiang, C., Ye, Y., Lin, H., & Fan, G. (2023). Senolytics prevent caveolar Ca V 3 . 2‐RyR axis malfunction in old vascular smooth muscle. Aging Cell, 22(11). https://doi.org/10.1111/acel.14002
Vancouver
Lin J, Guo W, Luo Q, Zhang Q, Wan T, Jiang C, et al. Senolytics prevent caveolar Ca V 3 . 2‐RyR axis malfunction in old vascular smooth muscle. Aging Cell. 2023;22(11). doi:10.1111/acel.14002
BibTeX
@article{Lin2023,
author = {Lin, Jie and Guo, Weiming and Luo, Qingtian and Zhang, Qingping and Wan, Teng and Jiang, Changyu and Ye, Yuanchun and Lin, Haihuan and Fan, Gang},
title = {Senolytics prevent caveolar Ca V 3 . 2‐RyR axis malfunction in old vascular smooth muscle},
journal = {Aging Cell},
year = {2023},
volume = {22},
number = {11},
doi = {10.1111/acel.14002}
}
EUVIMED